Lung Disease Associated With Rheumatoid Arthritis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001876|
Recruitment Status : Completed
First Posted : November 4, 1999
Last Update Posted : February 23, 2018
Pulmonary fibrosis (PF) is a condition in which the lungs of a patient become scarred and fibrous. It has been known to occur in as many as 40% of patients diagnosed with rheumatoid arthritis (RA). The cause of the pulmonary fibrosis in patients with RA is unknown.
Patients participating in this study will undergo a series of tests and examinations before and throughout the study. The tests include blood and urine tests, electrical measures of heart function (ECG), chest x-rays, CAT scans, nuclear medicine scans, breathing tests, exercise tests, and fiberoptic bronchoscopy.
The goals of this study are to:
- Estimate how common pulmonary fibrosis is in patients with rheumatoid arthritis,
- Describe the natural course of pulmonary fibrosis in patients with rheumatoid arthritis,
- Estimate the survival rate of patients with pulmonary fibrosis and rheumatoid arthritis, and
- Learn more about the factors that contribute to the development or progression fibrotic lung disease....
|Condition or disease|
|Pulmonary Fibrosis Rheumatoid Arthritis|
|Study Type :||Observational|
|Actual Enrollment :||132 participants|
|Official Title:||Pulmonary Fibrosis Associated With Rheumatoid Arthritis: Definition of the Natural History of Disease|
|Study Start Date :||March 1, 1999|
U.S. FDA Resources
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001876
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Bernadette R Gochuico, M.D.||National Human Genome Research Institute (NHGRI)|